You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


TG Therapeutics’ ublituximab tops Sanofi’s Aubagio in MS trial

New York-headquartered biopharma company TG Therapeutics has revealed new data for its investigational therapy ublituximab, which demonstrated superiority over Sanofi’s Aubagio in patients with relapsing forms of multiple sclerosis (MS).